An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 346-358

  Zhang, Yan ^a   Fang, Lin ^b   Zhang, Quan'an ^a   Zheng, Qin ^a   Tong, Jinlong ^a   Fu, Xiaohui ^c   Jiang, Xiaoqing ^c   Su, Changqing ^c   Zheng, Junnian ^b  

^a Nanjing Second Hospital   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Human sulfatase 1; Oncolytic adenovirus; Radiation inducible promoter; Radioimmunotherapy

Indexed keywords

CD147 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; ESTERASE; IODINE 131; METUXIMAB; MONOCLONAL ANTIBODY; ONCOLYTIC ADENOVIRUS; SULFATASE 1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84878111076     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.10.007     Document Type: Article

References (41)

1. Abiatari I., Kleeff J., Li J., Felix K., Büchler M.W., Friess H. Hsulf-1 regulates growth and invasion of pancreatic cancer cells. J. Clin. Pathol. 2006, 59:1052-1058.
2. Banerjee N.S., Rivera A.A., Wang M., Chow L.T., Broker T.R., Curiel D.T., Nettelbeck D.M. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol. Cancer Ther. 2004, 3:437-449.
3. Bickenbach K.A., Veerapong J., Shao M.Y., Mauceri H.J., Posner M.C., Kron S.J., Weichselbaum R.R. Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 2008, 15:133-139.
4. 131I metuximab injection: clinical phase I/II trials. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65:435-444.
5. Chen Z., Fan J.Q., Li J., Li Q.S., Yan Z., Jia X.K., Liu W.D., Wei L.J., Zhang F.Z., Gao H., Xu J.P., Dong X.M., Dai J., Zhou H.M. Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. Int. J. Cancer 2009, 124:739-744.
6. Chen N.G., Szalay A.A., Buller R.M., Lauer U.M. Oncolytic viruses. Adv. Virol. 2012, 2012:320206.
7. Cui H.Y., Guo T., Wang S.J., Zhao P., Dong Z.S., Zhang Y., Jiang J.L., Chen Z.N., Yu X.L. Dimerization is essential for HAb18G/CD147 promoting tumor invasion via MAPK pathway. Biochem. Biophys. Res. Commun. 2012, 419:517-522.
8. Dai J.Y., Dou K.F., Wang C.H., Zhao P., Lau W.B., Tao L., Wu Y.M., Tang J., Jiang J.L., Chen Z.N. The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer 2009, 9:337.
9. Dienstmann R., Markman B., Tabernero J. Application of monoclonal antibodies as cancer therapy in solid tumors. Curr. Clin. Pharmacol. 2012, 7:137-145.
10. Doloff J.C., Jounaidi Y., Waxman D.J. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther. 2011, 18:153-166.
11. Fraunholz I., Rödel C., Distel L., Rave-Fränk M., Kohler D., Falk S., Rödel F. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. Radiat. Oncol. 2012, 7:88.
12. Gou X., Ru Q., Zhang H., Chen Y., Li L., Yang H., Xing J., Chen Z. HAb18G/CD147 inhibits starvation-induced autophagy in human hepatoma cell SMMC7721 with an involvement of Beclin 1 down-regulation. Cancer Sci. 2009, 100:837-843.
13. Greco O., Marples B., Dachs G.U., Williams K.J., Patterson A.V., Scott S.D. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 2002, 9:1403-1411.
14. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
15. Hu H., Li Z., Chen J., Wang D., Ma J., Wang W., Li J., Wu H., Li L., Wu M., Qian Q., Chen J., Su C. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut 2011, 60:710-721.
16. Ji W., Yang J., Wang D., Cao L., Tan W., Qian H., Sun B., Qian Q., Yin Z., Wu M., Su C. hSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS One 2011, 6:e23274.
17. Khurana A., Liu P., Mellone P., Lorenzon L., Vincenzi B., Datta K., Yang B., Linhardt R.J., Lingle W., Chien J., Baldi A., Shridhar V. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res. 2011, 71:2152-2161.
18. LaBarre D.D., Lowy R.J. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J. Virol. Methods 2001, 96:107-126.
19. Lai J.P., Chien J.R., Moser D.R., Staub J.K., Aderca I., Montoya D.P., Matthews T.A., Nagorney D.M., Cunningham J.M., Smith D.I., Greene E.L., Shridhar V., Roberts L.R. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004, 126:231-248.
20. Liu C., Sun B., An N., Tan W., Cao L., Luo X., Yu Y., Feng F., Li B., Wu M., Su C., Jiang X. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Mol. Oncol. 2011, 5:545-554.
21. Liu H., Fu X., Ji W., Liu K., Bao L., Yan Y., Wu M., Yang J., Su C. Human sulfatase-1 inhibits the migration and proliferation of SMMC-7721 hepatocellular carcinoma cells by downregulating the growth factor signaling. Hepatol. Res. 2012, 10.1111/j.1872-034X.2012.01080.x.
22. Liu J., Fang L., Cheng Q., Li L., Su C., Zhang B., Pei D., Yang J., Li W., Zheng J. The effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell. Cancer Sci. 2012, 10.1111/j.1349-7006.2012.02380.x.
23. Ma J., He X., Wang W., Huang Y., Chen L., Cong W., Gu J., Hu H., Shi J., Li L., Su C. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig. Dis. Sci. 2009, 54:1425-1431.
24. Narita K., Chien J., Mullany S.A., Staub J., Qian X., Lingle W.L., Shridhar V. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J. Biol. Chem. 2007, 282:14413-14420.
25. Onimaru M., Ohuchida K., Nagai E., Mizumoto K., Egami T., Cui L., Sato N., Uchino J., Takayama K., Hashizume M., Tanaka M. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett. 2010, 294:178-186.
26. Prabhu S., Boswell C.A., Leipold D., Khawli L.A., Li D., Lu D., Theil F.P., Joshi A., Lum B.L. Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther. Deliv. 2011, 2:769-791.
27. Russell S.J., Peng K.W., Bell J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30:658-670.
28. Scott S.D., Marples B., Hendry J.H., Lashford L.S., Embleton M.J., Hunter R.D., Howell A., Margison G.P. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther. 2000, 7:1121-1125.
29. Staub J., Chien J., Pan Y., Qian X., Narita K., Aletti G., Scheerer M., Roberts L.R., Molina J., Shridhar V. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 2007, 26:4969-4978.
30. Wang B., Xu Y.F., He B.S., Pan Y.Q., Zhang L.R., Zhu C., Qu L.L., Wang S.K. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J. Exp. Clin. Cancer Res. 2010, 29:61.
31. Wong H.H., Jiang G., Gangeswaran R., Wang P., Wang J., Yuan M., Wang H., Bhakta V., Müller H., Lemoine N.R., Wang Y. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol. Ther. 2012, 20:306-316.
32. Wrzesinski S.H., Taddei T.H., Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin. Liver Dis. 2011, 15:423-441. (vii-x).
33. Wu L., Yang Y.F., Ge N.J., Shen S.Q., Liang J., Wang Y., Zhou W.P., Shen F., Wu M.C. Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients. Cancer Biother. Radiopharm. 2010, 25:657-663.
34. 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Eur. J. Nucl. Med. Mol. Imaging 2012, 39:1306-1315.
35. Xiong J., Sun W.J., Wang W.F., Liao Z.K., Zhou F.X., Kong H.Y., Xu Y., Xie C.H., Zhou Y.F. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 2012, 118:536-548.
36. Xu J., Xu H.Y., Zhang Q., Song F., Jiang J.L., Yang X.M., Mi L., Wen N., Tian R., Wang L., Yao H., Feng Q., Zhang Y., Xing J.L., Zhu P., Chen Z.N. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol. Cancer Res. 2007, 5:605-614.
37. Xu C., Sun Y., Wang Y., Yan Y., Shi Z., Chen L., Lin H., Lü S., Zhu M., Su C., Li Z. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett. 2012, 319:154-163.
38. Yang J.D., Sun Z., Hu C., Lai J., Dove R., Nakamura I., Lee J.S., Thorgeirsson S.S., Kang K.J., Chu I.S., Roberts L.R. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer 2011, 50:122-135.
39. Yoneda A., Lendorf M.E., Couchman J.R., Multhaupt H.A. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J. Histochem. Cytochem. 2012, 60:9-21.
40. Zhang K.J., Qian J., Wang S.B., Yang Y. Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. J. Biomed. Sci. 2012, 19:20.
41. Zhu H., Yang B., Yang X., Wang L., Xu J., Liao C., Feng Q., Tang H., Hu L., Chen Z., Li Y. A novel antibody fragment targeting HAb18G/CD147 with cytotoxicity and decreased immunogenicity. Cancer Biol. Ther. 2009, 8:1035-1044.